Dolutegravir in Pregnant HIV Mothers and Their Neonates (DolPHIN-2)
Sponsor: Infectious Diseases Institute, Uganda
A PHASE3 clinical study on HIV-1-infection and Pregnancy Related, this trial is completed. The trial is conducted by Infectious Diseases Institute, Uganda and has accumulated 12 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
12 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Infectious Diseases Institute, Uganda
- Liverpool School of Tropical Medicine
- Radboud University Medical Center
- UNITAID
- University of Cape Town
- University of Liverpool
For direct contact, visit the study record on ClinicalTrials.gov .